Certara
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 1.3K
- Market Cap
- -
- Introduction
Cerrado Gold Inc is a precious metals mining and exploration company building a portfolio of assets in South America. The company owns the Minera Don Nicolas Project, located in Santa Cruz, Argentina. It is also focused on exploration at its Monte do Carmo gold Project in Tocantins State, Brazil.
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
International Registry of Healthcare Workers Exposed to COVID-19 Patients (UNITY Global)
- Conditions
- Covid19SARS-CoV Infection
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Certara
- Target Recruit Count
- 6808
- Registration Number
- NCT04626076
- Locations
- 🇵🇰
Aga Khan University, Karachi, Pakistan
News
Certara Expands Clinical Technology Partnership with Merck to Streamline Data Management
Certara and Merck have expanded their clinical technology collaboration to include metadata repository and data standards workflow management through the Pinnacle 21 platform.
IRA Biosimilar Incentives Drive Measurable Uptake in US Healthcare Facilities
The Inflation Reduction Act's 2% Medicare reimbursement boost for qualifying biosimilars has led to measurable increases in adoption, with 45% of surveyed facilities reporting slight increases and 14% reporting significant increases in utilization.
Certara Launches Non-Animal Navigator Solution to Reduce Animal Testing in Drug Development
Certara has introduced the Non-Animal Navigator solution to help pharmaceutical companies reduce reliance on animal testing in preclinical safety studies, aligning with FDA's recent roadmap initiative.
AI Simulations Enhance Clinical Trial Efficiency and Accuracy in Drug Development
AI-driven simulations are improving clinical trial success rates by preemptively modeling trials and optimizing dosing strategies.